Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for patients with hematologic malignancies and solid tumors. Its pipeline includes rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy being studied in pivotal PiNACLE work in the 3L+ setting and in a Phase 1/2 trial in the 2L setting, as well as the PiNACLE-H2H Phase 3 head-to-head randomized trial in large B-cell lymphoma. The company is also advancing LYL273, a GCC-targeted CAR T-cell candidate with added CD19 CAR expression and controlled cytokine release, which is in Phase 1 development for refractory metastatic colorectal cancer. Lyell also applies several cell-engineering approaches, including c-Jun overexpression, NR4A3 gene knockout, Epi-R, and CD62L-positive enrichment, to improve CAR T-cell performance. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.